{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:30:02Z","timestamp":1791095402265,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,5,12]],"date-time":"2012-05-12T00:00:00Z","timestamp":1336780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s11904-012-0119-7","type":"journal-article","created":{"date-parts":[[2012,5,11]],"date-time":"2012-05-11T11:48:13Z","timestamp":1336736893000},"page":"218-222","source":"Crossref","is-referenced-by-count":42,"title":["Osteoporosis and Bone Health in HIV"],"prefix":"10.1007","volume":"9","author":[{"given":"William G.","family":"Powderly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,12]]},"reference":[{"key":"119_CR1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"FJ Palella Jr","year":"1998","unstructured":"Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853\u201360.","journal-title":"N Engl J Med"},{"key":"119_CR2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/QAD.0b013e3283365356","volume":"24","author":"J Neuhaus","year":"2010","unstructured":"Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS. 2010;24:697\u2013706.","journal-title":"AIDS"},{"key":"119_CR3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.beem.2010.11.003","volume":"25","author":"AG Cotter","year":"2011","unstructured":"Cotter AG, Powderly WG. Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab. 2011;25:501\u201315.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"119_CR4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137\u201341.","journal-title":"J Bone Miner Res"},{"key":"119_CR5","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","volume":"354","author":"E Seeman","year":"2006","unstructured":"Seeman E, Delmas PD. Bone quality\u2013the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250\u201361.","journal-title":"N Engl J Med"},{"key":"119_CR6","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.289.5484.1501","volume":"289","author":"P Ducy","year":"2000","unstructured":"Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000;289:1501\u20134.","journal-title":"Science"},{"key":"119_CR7","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","volume":"289","author":"SL Teitelbaum","year":"2000","unstructured":"Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504\u20138.","journal-title":"Science"},{"key":"119_CR8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:375\u201382.","journal-title":"Bone"},{"key":"119_CR9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878\u201382.","journal-title":"Lancet"},{"key":"119_CR10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/367569","volume":"36","author":"K Mondy","year":"2003","unstructured":"Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482\u201390.","journal-title":"Clin Infect Dis"},{"key":"119_CR11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1359\/JBMR.0301246","volume":"19","author":"C Amiel","year":"2004","unstructured":"Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004;19:402\u20139.","journal-title":"J Bone Miner Res"},{"key":"119_CR12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00002030-200104130-00005","volume":"15","author":"A Carr","year":"2001","unstructured":"Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 2001;15:703\u20139.","journal-title":"AIDS"},{"key":"119_CR13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00198-007-0524-8","volume":"19","author":"S Jones","year":"2008","unstructured":"Jones S, Restrepo D, Kasowitz A, et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int. 2008;19:913\u20138.","journal-title":"Osteoporos Int"},{"key":"119_CR14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00198-005-1845-0","volume":"16","author":"M Yin","year":"2005","unstructured":"Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int. 2005;16:1345\u201352.","journal-title":"Osteoporos Int"},{"key":"119_CR15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/QAD.0b013e3280148c05","volume":"21","author":"JH Arnsten","year":"2007","unstructured":"Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21:617\u201323.","journal-title":"AIDS"},{"key":"119_CR16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e3282f423dd","volume":"22","author":"C Cazanave","year":"2008","unstructured":"Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008;22:395\u2013402.","journal-title":"AIDS"},{"key":"119_CR17","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1210\/jc.2011-2197","volume":"97","author":"MT Yin","year":"2012","unstructured":"\u2022 Yin MT, Zhang CA, McMahon DJ, et al. Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metab. 2012;97:554\u201362. Further recent evidence of the additional risk associated with HIV, even in populations already at high risk of osteoporosis.","journal-title":"J Clin Endocrinol Metab"},{"key":"119_CR18","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/00002030-200309050-00010","volume":"17","author":"D Bruera","year":"2003","unstructured":"Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17:1917\u201323.","journal-title":"AIDS"},{"key":"119_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QCO.0b013e328334fe9a","volume":"23","author":"PW Mallon","year":"2010","unstructured":"Mallon PW. HIV and bone mineral density. Curr Opin Infect Dis. 2010;23:1\u20138.","journal-title":"Curr Opin Infect Dis"},{"key":"119_CR20","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","volume":"20","author":"TT Brown","year":"2006","unstructured":"Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165\u201374.","journal-title":"AIDS"},{"key":"119_CR21","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1210\/jc.2007-1660","volume":"92","author":"MJ Bolland","year":"2007","unstructured":"Bolland MJ, Grey AB, Gamble GD, Reid IR. Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2007;92:4522\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"119_CR22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e3282f423dd","volume":"22","author":"C Cazanave","year":"2008","unstructured":"Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008;22:395\u2013402.","journal-title":"AIDS"},{"key":"119_CR23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bone.2005.11.001","volume":"38","author":"A Fausto","year":"2006","unstructured":"Fausto A, Bongiovanni M, Cicconi P, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38:893\u20137.","journal-title":"Bone"},{"key":"119_CR24","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/QAD.0b013e32832c4947","volume":"23","author":"MG Vonderen van","year":"2009","unstructured":"van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, et al. First line zidovudine\/lamivudine\/lopinavir\/ritonavir leads to greater bone loss compared to nevirapine\/lopinavir\/ritonavir. AIDS. 2009;23:1367\u201376.","journal-title":"AIDS"},{"key":"119_CR25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","volume":"354","author":"JE Gallant","year":"2006","unstructured":"Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251\u201360.","journal-title":"N Engl J Med"},{"key":"119_CR26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","volume":"51","author":"HJ Stellbrink","year":"2010","unstructured":"Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963\u201372.","journal-title":"Clin Infect Dis"},{"key":"119_CR27","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","volume":"203","author":"G McComsey","year":"2011","unstructured":"\u2022 McComsey G, Kitch D, Daar E, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791\u2013801. Evidence from a randomized controlled trial that tenofovir is associated with increased rates of decreased bone density immediately after initiation of ART.","journal-title":"J Infect Dis"},{"key":"119_CR28","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/644769","volume":"49","author":"A Martin","year":"2009","unstructured":"Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49:1591\u2013601.","journal-title":"Clin Infect Dis"},{"key":"119_CR29","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1210\/jc.2011-0591","volume":"96","author":"MJ Bolland","year":"2011","unstructured":"Bolland MJ, Wang TK, Grey A, Gamble GD, Reid IR. Stable bone density in HAART-treated individuals with HIV: a meta-analysis. J Clin Endocrinol Metab. 2011;96:2721\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"119_CR30","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/QAD.0b013e32832c1792","volume":"23","author":"B Grund","year":"2009","unstructured":"Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23:1519\u201329.","journal-title":"AIDS"},{"key":"119_CR31","doi-asserted-by":"crossref","first-page":"e23688","DOI":"10.1371\/journal.pone.0023688","volume":"6","author":"AY Liu","year":"2011","unstructured":"Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6:e23688.","journal-title":"PLoS One"},{"key":"119_CR32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/QAI.0b013e3181caebaa","volume":"54","author":"MM Rosenvinge","year":"2010","unstructured":"Rosenvinge MM, Gedela K, Copas AJ, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr. 2010;54:496\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"119_CR33","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1210\/jc.2008-0828","volume":"93","author":"VA Triant","year":"2008","unstructured":"Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93:3499\u2013504.","journal-title":"J Clin Endocrinol Metab"},{"key":"119_CR34","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/QAD.0b013e3283292195","volume":"23","author":"F Collin","year":"2009","unstructured":"Collin F, Duval X, Le Moing V, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS. 2009;23:1021\u20134.","journal-title":"AIDS"},{"key":"119_CR35","doi-asserted-by":"crossref","first-page":"e17217","DOI":"10.1371\/journal.pone.0017217","volume":"6","author":"JA Womack","year":"2011","unstructured":"Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011;6:e17217.","journal-title":"PLoS One"},{"key":"119_CR36","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1097\/QAD.0b013e32833f6294","volume":"24","author":"MT Yin","year":"2010","unstructured":"Yin MT, Shi Q, Hoover DR, et al. Fracture incidence in HIV-infected women: results from the Women\u2019s Interagency HIV Study. AIDS. 2010;24:2679\u201386.","journal-title":"AIDS"},{"key":"119_CR37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/QAD.0b013e32834ed8a7","volume":"26","author":"AB Hansen","year":"2012","unstructured":"Hansen AB, Gerstoft J, Kronborg G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;26:285\u201393.","journal-title":"AIDS"},{"key":"119_CR38","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","volume":"26","author":"R Bedimo","year":"2012","unstructured":"\u2022 Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral gents. AIDS. 2012;26:825\u201331. First study to date to potentially link tenofovir use to increased risk of fracture.","journal-title":"AIDS."},{"key":"119_CR39","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/cid\/ciq242","volume":"52","author":"B Young","year":"2011","unstructured":"Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000\u20132006. Clin Infect Dis. 2011;52:1061\u20138.","journal-title":"Clin Infect Dis"},{"key":"119_CR40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/aid.2008.0183","volume":"25","author":"M Rodriguez","year":"2009","unstructured":"Rodriguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses. 2009;25:9\u201314.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"119_CR41","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1089\/aid.2008.0058","volume":"24","author":"CJ Bout-Van Den Beukel Van Den","year":"2008","unstructured":"Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1375\u201382.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"119_CR42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1468-1293.2007.00534.x","volume":"9","author":"JD Lundgren","year":"2008","unstructured":"Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008;9:72\u201381.","journal-title":"HIV Med"},{"key":"119_CR43","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1086\/656412","volume":"51","author":"GA McComsey","year":"2010","unstructured":"\u2022 McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937\u201346. State-of-the-art guidelines for screening and management of osteoporosis in HIV infection.","journal-title":"Clin Infect Dis"},{"key":"119_CR44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0025-6196(11)62214-3","volume":"77","author":"LA Fitzpatrick","year":"2002","unstructured":"Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77:453\u201368.","journal-title":"Mayo Clin Proc"},{"key":"119_CR45","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1310\/MD8V-5DLG-EN3T-BRHX","volume":"5","author":"G Guaraldi","year":"2004","unstructured":"Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia\/osteoporosis. HIV Clin Trials. 2004;5:269\u201377.","journal-title":"HIV Clin Trials"},{"key":"119_CR46","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.qai.0000145352.04440.1e","volume":"38","author":"K Mondy","year":"2005","unstructured":"Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia\/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38:426\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"119_CR47","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1097\/QAD.0b013e3282ef961d","volume":"21","author":"GA McComsey","year":"2007","unstructured":"McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007;21:2473\u201382.","journal-title":"AIDS"},{"key":"119_CR48","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1210\/jc.2006-2216","volume":"92","author":"MJ Bolland","year":"2007","unstructured":"Bolland MJ, Grey AB, Horne AM, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007;92:1283\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"119_CR49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/QAD.0b013e32831c8adc","volume":"23","author":"J Huang","year":"2009","unstructured":"Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2009;23:51\u20137.","journal-title":"AIDS"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-012-0119-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-012-0119-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-012-0119-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T11:45:04Z","timestamp":1561722304000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-012-0119-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,12]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["119"],"URL":"https:\/\/doi.org\/10.1007\/s11904-012-0119-7","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,12]]}}}